Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.
Estelamari Rodriguez, MD, MPH
Advertisement
Estelamari Rodriguez, MD, MPH, is the associate director of community outreach for thoracic oncology and the assistant director of diversity, equity, & inclusion at the University of Miami Sylvester Comprehensive Cancer Center.
Articles by Estelamari Rodriguez, MD, MPH
Subcutaneous amivantamab offers faster treatment, fewer infusion reactions, and improved convenience for patients with EGFR-mutated NSCLC, says Estelamari Rodriguez, MD, MPH.
The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, says Estelamari Rodriguez, MD, MPH.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
2
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
3
Amid SOHO Data, Reviewers of BTK Inhibitors in MCL Call for Trials
4
MFN Drug Agreements Could Raise Prices Worldwide
5